Connect with us

Hi, what are you looking for?

Jewish Business News


Technion breakthrough opens new avenues for Alzheimer’s cure

Head ,    pain,    man,    Image,    health


Alzheimer’s disease affects approximately 5.2 million people in the United States alone, and it is the nation’s sixth leading cause of death.  A cure for this insidious killer has so far proven elusive, but that could soon change as a result of a breakthrough at the Technion-Israel Institute of Technology that sheds light on a key mechanism in the accumulation of protein plaques in the tissue of Alzheimer’s disease patients.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

The findings were published online this week by Nature Chemical Biology.

“Proteins that constitute major building blocks of our body cells continuously pass through quality control, ” explains team leader Prof. Michael Glickman, of the Faculty of Biology. “Defective proteins are sent to the proteasome, a molecular machine (found in all of our cells) that eliminates defective proteins by recycling them back to their building blocks. But a small number of them slip through this process. Proteins that evade the proteasome accumulate, and may be harmful when they reach a critical mass, which is often the case at an advanced age.”

The researchers’ breakthrough findings are centered on UBB +1, a mutation prevalent in Alzheimer’s disease patients.  The mutation impairs a protein called ubiquitin* that marks other proteins to be dismantled at the proteasome.

Previously, the prevailing view among scientists was that UBB +1 impairs the functioning of the proteasome itself.  But in her doctoral dissertation under the guidance of Prof. Glickman, Dr. Daria Krutauz found that in the presence of UBB+1, damaged proteins are apprehended on their way to the proteasome, and accumulate without reaching their final recycling destination.  As a result, they have more opportunity to form the deadly plaque associated with Alzheimer’s disease.

“Because our findings run contrary to what was previously believed, this discovery opens new venues for intervention in the hope of developing a cure for Alzheimer’s disease, ” says Prof. Glickman.

The research team was comprised of Prof. Michael Glickman, Dr. Daria Krutauz and Lab Manager Noa Reis, in collaboration with team members in the labs of Prof. David Fushman at the University of Maryland, Prof. Steve Gygi at Harvard Medical School and Prof. Ashraf Brik at Ben Gurion University.


* In 2004, Distinguished Professors Avram Hershko and Aaron Ciechanover of the Technion, and Prof. Ernie Rose from the Fox Chase Institute were awarded the Nobel Prize in chemistry for their discovery of ubiquitin.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.